SlideShare a Scribd company logo
1 of 20
[object Object]
 The major causes of inter subject pharmacokinetic  variability are  :- 	,[object Object]
Age          1.Drug metabolism in new born        2.Plasma protein bonding in new born        3.Renal excretion in new born        4.Drug metabolism in children ,[object Object]
Disease,[object Object]
[object Object]
Drug binding, metabolism, and excretion may change as a function of age.
The study panel was divided into 5 groups:                        		              Newborns (2 to 3 days) 	          Infants (1 to 12 months)               Children (4 to 9 years)                Adults (16 to 37 years)                Elderly subjects (more than 70 years)
[object Object]
Clearance increased from 0.9 to 2.5 ml/min. when comparing patient 1 to 8 days old with patient 9 to 30  days old.
The mean clearance of ceftriaxone in children ranging in age from 1 to 12 months and from 1 to 6 years was 6.2 ml/min. and 9.1 ml/min. respectively.
The  18 to 49 years old age group had the highest clearance of ceftriaxone, 17 ml/min. ,[object Object]
Very elderly patients 75 to 92 years of age had an average clearance of about 8 ml/min.,[object Object]
Most of the enzymatic microsomal systems required for drug metabolism are present at birth, but their  concentration are usually lower than adult levels.
In  general drugs subject to  biotransformation are eliminated more slowly in newborn than in adult.,[object Object]
Sulfate conjugation seems to be as efficient in newborns as in adults, but conjugation with glucuronic acid is considerably reduced, reaching adult level only after 3 years of age.
This deficiency is responsible for the serious adverse effects observed in newborn after administration of chloramphenicol a drug that is ordinarily conjugated with glucuroni acid.  ,[object Object]
The amount of unchanged theophylline in urine in premature infants decreases with postnatal age, whereas the excretion of metabolites increases with age. ,[object Object]
In each case binding in plasma protein is level in the newborns than in the adults.
Increase in plasma protein binding is an increase in apparent volume of distribution in the newborn.

More Related Content

What's hot

35 effects of renal disease on pharmacokinetics
35 effects of renal disease on pharmacokinetics35 effects of renal disease on pharmacokinetics
35 effects of renal disease on pharmacokinetics
Dang Thanh Tuan
 

What's hot (20)

Pharmacokinetic changes in renal impairment and dosage considerations
Pharmacokinetic changes in renal impairment and dosage considerationsPharmacokinetic changes in renal impairment and dosage considerations
Pharmacokinetic changes in renal impairment and dosage considerations
 
Pharmacodynamics and kinetics during pregnancy
Pharmacodynamics and kinetics during pregnancyPharmacodynamics and kinetics during pregnancy
Pharmacodynamics and kinetics during pregnancy
 
Pharmacodynamic interactions
Pharmacodynamic interactionsPharmacodynamic interactions
Pharmacodynamic interactions
 
Pharmacokinetics of drug interaction
Pharmacokinetics of drug interactionPharmacokinetics of drug interaction
Pharmacokinetics of drug interaction
 
Individualization of drug dosage regimen
Individualization of drug dosage regimenIndividualization of drug dosage regimen
Individualization of drug dosage regimen
 
Dose adjustment in Renal Disorders
Dose adjustment in Renal DisordersDose adjustment in Renal Disorders
Dose adjustment in Renal Disorders
 
Bioavailability testing protocol
Bioavailability testing protocolBioavailability testing protocol
Bioavailability testing protocol
 
35 effects of renal disease on pharmacokinetics
35 effects of renal disease on pharmacokinetics35 effects of renal disease on pharmacokinetics
35 effects of renal disease on pharmacokinetics
 
Individualization of dosage regimen
Individualization of dosage regimenIndividualization of dosage regimen
Individualization of dosage regimen
 
pharmacokinetic drug interactions
 pharmacokinetic drug interactions pharmacokinetic drug interactions
pharmacokinetic drug interactions
 
Inhibition and induction of drug metabolism @ RxVichuZ!! ;)
Inhibition and induction of drug metabolism @ RxVichuZ!! ;)Inhibition and induction of drug metabolism @ RxVichuZ!! ;)
Inhibition and induction of drug metabolism @ RxVichuZ!! ;)
 
Importance of clinical pharmacokinetic studies
Importance of clinical pharmacokinetic studiesImportance of clinical pharmacokinetic studies
Importance of clinical pharmacokinetic studies
 
Pharmacokinetic and Pharmacodynamic Modeling
Pharmacokinetic and Pharmacodynamic ModelingPharmacokinetic and Pharmacodynamic Modeling
Pharmacokinetic and Pharmacodynamic Modeling
 
CARBAMAZEPINE TDM: @ RxVichuZ!! ;)
CARBAMAZEPINE TDM: @ RxVichuZ!! ;)CARBAMAZEPINE TDM: @ RxVichuZ!! ;)
CARBAMAZEPINE TDM: @ RxVichuZ!! ;)
 
PK and Drug Therapy in pediatrics, geriatrics and pregnancy & Lactation
PK and Drug Therapy in pediatrics, geriatrics and pregnancy & LactationPK and Drug Therapy in pediatrics, geriatrics and pregnancy & Lactation
PK and Drug Therapy in pediatrics, geriatrics and pregnancy & Lactation
 
Birth defect due to drugs
Birth defect due to drugsBirth defect due to drugs
Birth defect due to drugs
 
Geriatric,obese and pediatric patients Pharmacokinetics
Geriatric,obese and pediatric patients PharmacokineticsGeriatric,obese and pediatric patients Pharmacokinetics
Geriatric,obese and pediatric patients Pharmacokinetics
 
pharmacokinetic drug interaction and induction and inhibition of drug metabolism
pharmacokinetic drug interaction and induction and inhibition of drug metabolismpharmacokinetic drug interaction and induction and inhibition of drug metabolism
pharmacokinetic drug interaction and induction and inhibition of drug metabolism
 
Effects of liver diseases on pharmacokinetics
Effects of liver diseases on pharmacokineticsEffects of liver diseases on pharmacokinetics
Effects of liver diseases on pharmacokinetics
 
Adaptive method OR dosing with feedback
Adaptive method OR dosing with feedbackAdaptive method OR dosing with feedback
Adaptive method OR dosing with feedback
 

Viewers also liked

Applications of pharmacokinetics parameters in disease states
Applications of pharmacokinetics parameters in disease statesApplications of pharmacokinetics parameters in disease states
Applications of pharmacokinetics parameters in disease states
Umair hanif
 
Therapeutic Drug Monitoring
Therapeutic Drug MonitoringTherapeutic Drug Monitoring
Therapeutic Drug Monitoring
Tulasi Raman
 
Clinical pharmacology in special populations 2014
Clinical pharmacology in special populations 2014Clinical pharmacology in special populations 2014
Clinical pharmacology in special populations 2014
vanessawhitehawk
 

Viewers also liked (20)

Applications of pharmacokinetics parameters in disease states
Applications of pharmacokinetics parameters in disease statesApplications of pharmacokinetics parameters in disease states
Applications of pharmacokinetics parameters in disease states
 
Introduction to dosage regimen and Individualization of dosage regimen
Introduction to dosage regimen and Individualization of dosage regimenIntroduction to dosage regimen and Individualization of dosage regimen
Introduction to dosage regimen and Individualization of dosage regimen
 
Obsity
ObsityObsity
Obsity
 
Factors affecting pharmacokinetic parameters
Factors affecting pharmacokinetic parametersFactors affecting pharmacokinetic parameters
Factors affecting pharmacokinetic parameters
 
Dosage Regimen
Dosage RegimenDosage Regimen
Dosage Regimen
 
Therapeutic drug monitoring
Therapeutic drug monitoringTherapeutic drug monitoring
Therapeutic drug monitoring
 
Dosage regimen
Dosage regimenDosage regimen
Dosage regimen
 
Therapeutic Drug Monitoring
Therapeutic Drug MonitoringTherapeutic Drug Monitoring
Therapeutic Drug Monitoring
 
Trouble Shooting of Chemical Process Industry
Trouble Shooting of Chemical Process IndustryTrouble Shooting of Chemical Process Industry
Trouble Shooting of Chemical Process Industry
 
Pharmacokinetic changes of drugs in hepatic diseases
Pharmacokinetic changes of drugs in hepatic diseasesPharmacokinetic changes of drugs in hepatic diseases
Pharmacokinetic changes of drugs in hepatic diseases
 
Renal Clearance
Renal ClearanceRenal Clearance
Renal Clearance
 
Pharmacokinetics In Special Populations
Pharmacokinetics In Special PopulationsPharmacokinetics In Special Populations
Pharmacokinetics In Special Populations
 
Pharmacokinetics (updated 2011) - drdhriiti
Pharmacokinetics (updated 2011)  - drdhriitiPharmacokinetics (updated 2011)  - drdhriiti
Pharmacokinetics (updated 2011) - drdhriiti
 
Design and optimizing of dosage regimen - pharmacology
Design and optimizing of dosage regimen - pharmacology Design and optimizing of dosage regimen - pharmacology
Design and optimizing of dosage regimen - pharmacology
 
Renal clearance
Renal clearanceRenal clearance
Renal clearance
 
Pilot plant scale up techniques used in pharmaceutical manufacturing
Pilot plant scale up techniques used in pharmaceutical manufacturingPilot plant scale up techniques used in pharmaceutical manufacturing
Pilot plant scale up techniques used in pharmaceutical manufacturing
 
excretion
excretionexcretion
excretion
 
Clinical pharmacology in special populations 2014
Clinical pharmacology in special populations 2014Clinical pharmacology in special populations 2014
Clinical pharmacology in special populations 2014
 
Pharmacokinetics of multiple dosing
Pharmacokinetics of multiple dosingPharmacokinetics of multiple dosing
Pharmacokinetics of multiple dosing
 
DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES
DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASESDRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES
DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES
 

Similar to Pharmacokinetic variability

Drug therapy-Neonates and pediatrics
Drug therapy-Neonates and pediatricsDrug therapy-Neonates and pediatrics
Drug therapy-Neonates and pediatrics
Tsegaye Melaku
 
Pharmacology for pediatric anaesthesia [autosaved]
Pharmacology for pediatric anaesthesia [autosaved]Pharmacology for pediatric anaesthesia [autosaved]
Pharmacology for pediatric anaesthesia [autosaved]
DeepakGupta825
 
Clinical trial in special population final
Clinical trial in special population finalClinical trial in special population final
Clinical trial in special population final
anupam raghunath
 

Similar to Pharmacokinetic variability (20)

Clinical Pharmacokinetics
Clinical PharmacokineticsClinical Pharmacokinetics
Clinical Pharmacokinetics
 
Paediatric pharmaco-kinetics
Paediatric pharmaco-kinetics Paediatric pharmaco-kinetics
Paediatric pharmaco-kinetics
 
Drug therapy in children
Drug therapy in childrenDrug therapy in children
Drug therapy in children
 
Analgesic in Pedo-Part 1.pptx
Analgesic in Pedo-Part 1.pptxAnalgesic in Pedo-Part 1.pptx
Analgesic in Pedo-Part 1.pptx
 
Drug distribution in pediatrics
Drug distribution in pediatricsDrug distribution in pediatrics
Drug distribution in pediatrics
 
Pediatric drug for clinical pharmacy student 1
Pediatric drug for clinical pharmacy student 1Pediatric drug for clinical pharmacy student 1
Pediatric drug for clinical pharmacy student 1
 
Neonatal pediatric-pharmacology
Neonatal pediatric-pharmacologyNeonatal pediatric-pharmacology
Neonatal pediatric-pharmacology
 
Individualization of drug
Individualization of drugIndividualization of drug
Individualization of drug
 
Drug therapy-Neonates and pediatrics
Drug therapy-Neonates and pediatricsDrug therapy-Neonates and pediatrics
Drug therapy-Neonates and pediatrics
 
Paediatrics
PaediatricsPaediatrics
Paediatrics
 
Pediatric pharmacotherapy
Pediatric pharmacotherapyPediatric pharmacotherapy
Pediatric pharmacotherapy
 
prescribing in paediatrics.pptx
prescribing in paediatrics.pptxprescribing in paediatrics.pptx
prescribing in paediatrics.pptx
 
Drug use in paediatric & geriatric patients
Drug use in paediatric & geriatric patientsDrug use in paediatric & geriatric patients
Drug use in paediatric & geriatric patients
 
Clinical pharmacy age factors : Features of the Rational use of Medicines
Clinical pharmacy age factors : Features of the Rational use of MedicinesClinical pharmacy age factors : Features of the Rational use of Medicines
Clinical pharmacy age factors : Features of the Rational use of Medicines
 
Pharmacology for pediatric anaesthesia [autosaved]
Pharmacology for pediatric anaesthesia [autosaved]Pharmacology for pediatric anaesthesia [autosaved]
Pharmacology for pediatric anaesthesia [autosaved]
 
Paediatric Pharmacology Part-2.pptx
Paediatric Pharmacology Part-2.pptxPaediatric Pharmacology Part-2.pptx
Paediatric Pharmacology Part-2.pptx
 
Clinical trial in special population final
Clinical trial in special population finalClinical trial in special population final
Clinical trial in special population final
 
paeds drug drug calculation and formulas
paeds drug drug calculation and formulaspaeds drug drug calculation and formulas
paeds drug drug calculation and formulas
 
Principles of pharmacotherapy in neonates and paediatric population21
Principles of pharmacotherapy in neonates and paediatric population21Principles of pharmacotherapy in neonates and paediatric population21
Principles of pharmacotherapy in neonates and paediatric population21
 
P'kinetics &; drug therapy
P'kinetics  &; drug therapyP'kinetics  &; drug therapy
P'kinetics &; drug therapy
 

Recently uploaded

1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdf
QucHHunhnh
 
Making and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdfMaking and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdf
Chris Hunter
 
Beyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactBeyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global Impact
PECB
 

Recently uploaded (20)

1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdf
 
Unit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptxUnit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptx
 
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
 
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxBasic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
 
Introduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsIntroduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The Basics
 
Application orientated numerical on hev.ppt
Application orientated numerical on hev.pptApplication orientated numerical on hev.ppt
Application orientated numerical on hev.ppt
 
Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdf
 
Measures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeMeasures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and Mode
 
Grant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy ConsultingGrant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy Consulting
 
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
 
ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.
 
Python Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxPython Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docx
 
Making and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdfMaking and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdf
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdf
 
INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptxINDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
 
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
 
microwave assisted reaction. General introduction
microwave assisted reaction. General introductionmicrowave assisted reaction. General introduction
microwave assisted reaction. General introduction
 
Beyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactBeyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global Impact
 
Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17
 

Pharmacokinetic variability

  • 1.
  • 2.
  • 3.
  • 4.
  • 5.
  • 6.
  • 7. Drug binding, metabolism, and excretion may change as a function of age.
  • 8. The study panel was divided into 5 groups: Newborns (2 to 3 days) Infants (1 to 12 months) Children (4 to 9 years) Adults (16 to 37 years) Elderly subjects (more than 70 years)
  • 9.
  • 10. Clearance increased from 0.9 to 2.5 ml/min. when comparing patient 1 to 8 days old with patient 9 to 30 days old.
  • 11. The mean clearance of ceftriaxone in children ranging in age from 1 to 12 months and from 1 to 6 years was 6.2 ml/min. and 9.1 ml/min. respectively.
  • 12.
  • 13.
  • 14. Most of the enzymatic microsomal systems required for drug metabolism are present at birth, but their concentration are usually lower than adult levels.
  • 15.
  • 16. Sulfate conjugation seems to be as efficient in newborns as in adults, but conjugation with glucuronic acid is considerably reduced, reaching adult level only after 3 years of age.
  • 17.
  • 18.
  • 19. In each case binding in plasma protein is level in the newborns than in the adults.
  • 20. Increase in plasma protein binding is an increase in apparent volume of distribution in the newborn.
  • 21.
  • 22.
  • 23. The difference process of renal excretion on mature at different rates,
  • 24. Average glomerular filtration rate is 38.5 ml/min.
  • 25.
  • 26.
  • 27. Older infants age (6 months to 12 years) has higher drug metabolism capacity rates compared to adults. for example, clindamycin theophylline valproic acid Has faster elimination rate.
  • 28.
  • 29. Formula used to determine dosage form
  • 30. Child dose= SA of child(m²) ------------------------------
  • 31.
  • 32. The increase in gastric ph, the decrease in gastric emptying rate and the slower motility associated with pregnancy can affect the rate and extent of drug absorption.
  • 33.